Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here’s why.

Related Keywords

Florida ,United States ,Chris Shibutani ,Andrew Baum ,Eli Lilly ,Seamus Fernandez ,Goldman Sachs ,Drug Administration ,Novo Nordisk ,South Florida ,News ,